OST tADC FRa-H
Alternative Names: OST-tADC-FRa-HLatest Information Update: 27 Sep 2024
Price :
$50 *
At a glance
- Originator OS Therapies
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Preclinical Ovarian cancer